Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report |
| |
Authors: | Hideki Yokoo Hiroyuki Takahashi Masahiro Hagiwara Hiroyoshi Iwata Koji Imai Yoshinori Saito Naoto Matsuno Hiroyuki Furukawa |
| |
Institution: | Hideki Yokoo, Hiroyuki Takahashi, Masahiro Hagiwara, Hiroyoshi Iwata, Koji Imai, Naoto Matsuno, Hiroyuki Furukawa, Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, JapanYoshinori Saito, Department of Gastroenterology, Asahikawa-Kosei General Hospital, Asahikawa 078-8211, Hokkaido, Japan |
| |
Abstract: | BACKGROUNDLenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However, the outcomes of such surgery are unknown. We report a successful case of hepatic resection for recurrent HCC after lenvatinib treatment.CASE SUMMARYA 69-year-old man underwent right anterior sectionectomy for HCC in segment 8 of the liver. Ten months later, he was found to have an intrahepatic HCC recurrence that grew rapidly to 10 cm in diameter with sternal bone metastases. After confirming partial response to lenvatinib administration for 2 mo, a second hepatectomy was performed. Pathological examination showed that 80% of the tumor was necrotic. The patient did not develop any adverse effects under lenvatinib treatment. He was discharged at 25 d after surgery. Radiation therapy for bone metastases continued to be given under lenvatinib, and the patient has remained alive for 1 year after the second hepatectomy.CONCLUSIONThe prognosis of patients with recurrent HCC may be improved by liver resection combined with prior lenvatinib therapy. |
| |
Keywords: | Conversion to surgery Lenvatinib Recurrent hepatocellular carcinoma Case report Neoadjuvant therapy Molecular targeted therapy |
|
| 点击此处可从《World journal of hepatology》浏览原始摘要信息 |
|